GlassScriptPhysician profile
Homer K Lew
NPI 1154452142
$2,736.26
in general payments reported to CMS, 2019-2025
32 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $312 · 2021: $580 · 2022: $479 · 2023: $422 · 2024: $281 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $992.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $370.40 | 2019-2025 | Evenity, Prolia, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $227.89 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $212.75 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $168.46 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $161.75 | 2021-2025 | Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $150.08 | 2020-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Abbvie INC. | $127.43 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.47 | 2019-2024 | Xifaxan |
| Lundbeck LLC | $111.17 | 2023-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $109.01 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $89.49 | 2019-2021 | |
| Inari Medical, INC. | $88.34 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Eisai INC. | $74.78 | 2020-2022 | |
| Biogen, INC. | $64.53 | 2021 | |
| Exact Sciences Corporation | $54.88 | 2023-2025 | Cologuard Collection Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $53.34 | 2019-2023 | |
| Pfizer INC. | $52.87 | 2021-2025 | |
| Radius Health, INC. | $52.72 | 2019-2020 | |
| Allergan, INC. | $52.59 | 2019-2020 | |
| Amarin Pharma, INC. | $50.73 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $49.08 | 2022-2023 | Crysvita |
| Lilly USA, LLC | $43.66 | 2024-2025 | Kisunla, Amyvid |
| Sun Pharmaceutical Industries INC. | $40.98 | 2021 | |
| Glaxosmithkline, LLC. | $40.49 | 2023-2025 | Shingrix, Arexvy |
| Boston Scientific Corporation | $28.47 | 2019-2022 | |
| Seqirus USA INC | $28.05 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $27.19 | 2022 | |
| Alexion Pharmaceuticals, INC. | $25.50 | 2021 | |
| Stryker Corporation | $17.62 | 2025 | Ivas |
| Tactile Systems Technology INC | $16.47 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.57 | 2022 | |
| Endogastric Solutions, INC | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Homer Lew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.